3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study. (September 2015) - Camidge, D.R.; Bazhenova, L.A.; Salgia, R.; Langer, C.J.; Gold, K.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Dorer, D.J.; Rivera, V.M.; Conlan, M.G.; Kerstein, D.; et al.